Combination Atezolizumab + FOLFOX Improves DFS in Stage III dMMR Colon Cancer in ATOMIC Trial

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the ATOMIC trial, which assessed the efficacy and safety of atezolizumab combined with standard chemotherapy in patients with stage III colon cancer with deficient DNA mismatch repair. This abstract will be presented as LBA1 during the Plenary Session at the 2025 ASCO Annual Meeting. Read the full abstract: https://meetings.asco.org/abstracts-presentations/245969 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 19, 2025_

Video Lainnya